Literature DB >> 17846974

Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.

G Rudofsky1, P Reismann, I A Grafe, I Konrade, Z Djuric, J Tafel, S Buchbinder, M Zorn, P M Humpert, A Hamann, M Morcos, P P Nawroth, A Bierhaus.   

Abstract

Thiazolidinediones such as pioglitazone have been shown to exert anti-inflammatory effects independent of their insulin sensitizing effects by reducing activation of the proinflammatory transcription factor NF-kappaB in animal models of experimental diabetes. Furthermore, short-term pioglitazone treatment ameliorates endothelial dysfunction in conduit arteries of patients with type 2 diabetes. Since inflammation is supposed to impair flow-mediated vasodilatation, we studied the effects of an 8-week pioglitazone intervention on endothelial function and mononuclear NF-kappaB activation in patients with type 2 diabetes. Twenty patients were included in a randomized, double-blind, placebo-controlled study receiving 30 mg pioglitazone or placebo, respectively. Flow-mediated endothelium dependent vasodilatation (FMD) of the brachial artery, NF-kappaB binding activity in peripheral blood mononuclear cells [pBMC, determined by electrophoretic mobility shift assay (EMSA)] and interleukin-6 (IL-6)-transcription rates (determined by real-time PCR) were measured at study entry and after eight weeks of intervention. Pioglitazone treatment resulted in a significant improvement of FMD (4.3%+/-3.3; p=0.003), while no effect was seen under placebo medication (2.0%+/-2.7; p=0.71). The correction of FMD was neither paralleled by a pioglitazone-dependent reduction in mononuclear NF-kappaB binding activity (DeltaNF-kappaB activity: pioglitazone: 9.2%+/-6.7, p=0.24; placebo: 5.7%+/-19.6; p=0.82) nor in NF-kappaB dependent gene transcription as determined for IL-6 (DeltaIL-6 pioglitazone: +1.8%+/-12.0, p=0.93; placebo: -0.2%+/-9.7; p=0.92). These data demonstrate for the first time that pioglitazone treatment improves endothelial dysfunction in patients with type 2 diabetes without affecting NF-kappaB binding activity and NF-kappaB dependent proinflammatory gene expression in pBMC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846974     DOI: 10.1055/s-2007-985395

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  4 in total

Review 1.  Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials.

Authors:  Marko Stojanović; Milica Prostran; Miroslav Radenković
Journal:  Eur J Clin Pharmacol       Date:  2015-12-22       Impact factor: 2.953

2.  Nuclear factor erythroid-derived 2 (Nfe2) regulates JunD DNA-binding activity via acetylation: a novel mechanism regulating trophoblast differentiation.

Authors:  Muhammed Kashif; Andrea Hellwig; Said Hashemolhosseini; Varun Kumar; Fabian Bock; Hongjie Wang; Khurrum Shahzad; Satish Ranjan; Juliane Wolter; Thati Madhusudhan; Angelika Bierhaus; Peter Nawroth; Berend Isermann
Journal:  J Biol Chem       Date:  2011-12-15       Impact factor: 5.157

Review 3.  The vascular endothelium in diabetes--a therapeutic target?

Authors:  Kieren J Mather
Journal:  Rev Endocr Metab Disord       Date:  2013-03       Impact factor: 6.514

4.  S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4.

Authors:  David Rohde; Christoph Schön; Melanie Boerries; Ieva Didrihsone; Julia Ritterhoff; Katharina F Kubatzky; Mirko Völkers; Nicole Herzog; Mona Mähler; James N Tsoporis; Thomas G Parker; Björn Linke; Evangelos Giannitsis; Erhe Gao; Karsten Peppel; Hugo A Katus; Patrick Most
Journal:  EMBO Mol Med       Date:  2014-04-06       Impact factor: 12.137

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.